In 1982, mutationally activated RAS genes were detected in human cancers, marking the first discovery of mutated genes in this disease 1 . Subsequent intensive sequencing of the cancer genome has revealed that, despite the identification of more than 500 validated cancer genes 2 (per the COSMIC (catalogue of somatic mutations in cancer) database), the three RAS genes (HRAS, NRAS and KRAS) still constitute the most frequently mutated oncogene family in human cancers (TABLE 1; see Supplementary information S1, S2 (tables)). The frequent mutation of RAS in three of the four most lethal cancers (lung, colon and pancreatic cancers) in the United States has spurred intense interest and effort in developing RAS inhibitors. However, despite more than three decades of effort by academia and industry, no effective RAS inhibitor has been approved, which has prompted a widely held perception that RAS oncoproteins are an 'undruggable' cancer target. Although past failures have dampened enthusiasm for the discovery of RAS inhibitors, mutated RAS proteins clearly merit continued attention. Given that the greatest success in signaltransduction-based therapies has been achieved against mutationally activated targets, there is now renewed hope that recent advances in understanding RAS function, together with new approaches and technologies, may finally have brought the holy grail of cancer research within reach 3 .
In 1982, mutationally activated RAS genes were detected in human cancers, marking the first discovery of mutated genes in this disease 1 . Subsequent intensive sequencing of the cancer genome has revealed that, despite the identification of more than 500 validated cancer genes 2 (per the COSMIC (catalogue of somatic mutations in cancer) database), the three RAS genes (HRAS, NRAS and KRAS) still constitute the most frequently mutated oncogene family in human cancers (TABLE 1; see Supplementary information S1, S2 (tables)). The frequent mutation of RAS in three of the four most lethal cancers (lung, colon and pancreatic cancers) in the United States has spurred intense interest and effort in developing RAS inhibitors. However, despite more than three decades of effort by academia and industry, no effective RAS inhibitor has been approved, which has prompted a widely held perception that RAS oncoproteins are an 'undruggable' cancer target. Although past failures have dampened enthusiasm for the discovery of RAS inhibitors, mutated RAS proteins clearly merit continued attention. Given that the greatest success in signaltransduction-based therapies has been achieved against mutationally activated targets, there is now renewed hope that recent advances in understanding RAS function, together with new approaches and technologies, may finally have brought the holy grail of cancer research within reach 3 .
In this Review, we provide a critical assessment of past efforts and discuss the most promising directions for future success (FIG. 1) . Firstly, we begin with what was once thought impossible: the direct inhibition of RAS. Secondly, we discuss the prospects for blocking RAS membrane association -a direction that lost favour following the disappointing clinical outcome of farnesyltransferase inhibitors (FTIs) 4 . Thirdly, we provide a status report on inhibitors of RAS downstream effector signalling, particularly signalling through RAF and phosphoinositide 3-kinase (PI3K). Fourthly, we summarize the efforts that have been made in the search for genes that interact with mutant RAS in a synthetic lethal manner, and we discuss whether this direction might yield alternative drug targets. We next evaluate the prospect that RAS-mediated changes in cell metabolism could be exploited for drug discovery. We conclude with a discussion of unresolved issues that will probably add complexity and further challenges to the discovery of drugs that target altered RAS pathway activation.
RAS mutations and human cancer RAS mutations are genetic events that occur early in tumour progression. Numerous genetically engineered mouse models of RAS-driven cancers have shown the potent cancer-inducing activity of mutant RAS. Loss of tumour suppressor function (for example, loss of tumour 1 Abstract | Despite more than three decades of intensive effort, no effective pharmacological inhibitors of the RAS oncoproteins have reached the clinic, prompting the widely held perception that RAS proteins are 'undruggable'. However, recent data from the laboratory and the clinic have renewed our hope for the development of RAS-inhibitory molecules. In this Review, we summarize the progress and the promise of five key approaches. Firstly, we focus on the prospects of using direct inhibitors of RAS. Secondly, we address the issue of whether blocking RAS membrane association is a viable approach. Thirdly, we assess the status of targeting RAS downstream effector signalling, which is arguably the most favourable current approach. Fourthly, we address whether the search for synthetic lethal interactors of mutant RAS still holds promise. Finally, RAS-mediated changes in cell metabolism have recently been described and we discuss whether these changes could be exploited for new therapeutic directions. We conclude with perspectives on how additional complexities, which are not yet fully understood, may affect each of these approaches.
Undruggable
Druggable biological targets such as some proteins can be bound with high affinity by small molecules, natural products, or antibodies in such a way that the binding then alters target function to achieve a therapeutic benefit. Undruggable targets are not amenable to such interventions.
RNA interference (RNAi) . A method of gene silencing in which short, double-stranded RNA molecules degrade target mRNAs in a sequence-specific manner to inhibit the expression and function of genes of interest.
protein p53 (TP53), LKB1 (also known as STK11) or adenomatous polyposis coli (APC)) together with RAS activation results in enhanced tumour formation and progression, which is consistent with the need for additional genetic alterations to cooperate with mutant RAS to fully transform cells [5] [6] [7] . Despite the early onset of RAS mutations, there is considerable experimental evidence to suggest that continued expression of mutant RAS is necessary for tumour maintenance. Suppression of RAS by RNA interference (RNAi) was shown to impair the in vitro and in vivo growth of RAS-mutant human cancer cell lines [8] [9] [10] . Similarly, in mouse models driven by inducible mutant RAS, withdrawal of RAS expression leads to tumour regression [11] [12] [13] [14] [15] . Therefore, there is little doubt that mutant RAS is a therapeutically useful drug target even in advanced metastatic tumours. Until recently, RAS-mutant cancers were discussed as if they comprised a homogeneous subset of all cancers; rather, there is now an emerging understanding that not all mutant RAS genes are created equal. Both the frequency with which each RAS isoform is mutated and the specific mutations thereof vary strikingly in different cancer types (BOX 1; Supplementary information S3 (figure)). Therapeutic approaches may need to be tailored to both the specific RAS isoform and the specific RAS mutation. Thus, there may not be a single RAS-targeted therapy that fits all RAS-mutant cancers.
In search of the Achilles' heel of RAS In order to develop antagonists of RAS, it is essential to understand the molecular requirements for RAS function. The canonical properties of RAS are those of a small GTPase that normally cycles between a GTP-bound active state and a GDP-bound inactive state, which is partly facilitated by the stimulation of GTP hydrolysis by GTPase-activating proteins (GAPs). However, when RAS proteins are mutationally activated, impaired GAP stimulation favours the formation of persistently GTPbound RAS 16 
. It was this important biochemical defect that prompted the earliest efforts to target mutant RAS in tumours. In an attempt to replicate the success of the ATP-competitive inhibitors that are effective antagonists of protein kinases, the identification of GTP-competitive inhibitors of RAS has been attempted. However, whereas ATP binds protein kinases with low micromolar affinity, GTP binds RAS proteins with picomolar affinity, which prevents the discovery of effective inhibitors. In another early effort, small molecules that could function as GAPs for mutant RAS were sought; however, these efforts have so far not succeeded 17 .
Another key requirement for RAS function is its association with the inner face of the plasma membrane 18
, for which it is obligatory that RAS is modified by addition of a C15 farnesyl isoprenoid lipid to its carboxy-terminal CAAX motif. The identification of farnesyltransferase (FTase) and the determination that the C-terminal CAAX tetrapeptide sequence alone was sufficient to inhibit FTase activity 19 prompted an intensive effort to develop FTIs 4 . Many potent and selective FTIs were shown in preclinical mouse studies to effectively block the growth of Hras-driven tumours. These remarkable results led to the clinical development of two FTIs (lonafarnib and tipifarnib), which advanced to Phase III clinical trials. However, these FTIs showed no antitumour activity in clinical trials focused on pancreatic and colon cancers, which are associated with mutations in KRAS or NRAS rather than HRAS (BOX 1; TABLE 1; Supplementary information S3 (figure)). One basis for this failure was predicted years earlier when it was unexpectedly found that, when FTase activity is blocked by FTI treatment, KRAS4B and NRAS proteins are no longer farnesylated but instead become substrates for the related prenyltransferase geranylgeranyltransferase I (GGTase I) that catalyses addition of a C20 geranylgeranyl isoprenoid group [20] [21] [22] , a process known as alternative prenylation. As this alternative lipid can also support their membrane association and oncogenic activities, KRAS4B and NRAS escape FTI-mediated inhibition of their function. The failure of this extensive effort to develop FTIs as RAS-targeted drugs created a stigma surrounding other ideas for blocking RAS membrane association. Indeed, the failure of FTIs to function as RAS-targeted drugs also prompted a surprisingly widely held misconception that RAS is not a useful therapeutic target. However, it did provide clues that conflating all of the RAS isoforms together would be an oversimplification.
The third key requirement for RAS function is the engagement of effector proteins that transmit signals downstream. The GTP-bound form of RAS is the active form by virtue of its increased affinity for effectors. At least 11 distinct classes of RAS effectors have so far been identified. The majority of these possess RAS-binding domains (RBDs) or RAS-association (RA) domains 23 . Association with RAS-GTP promotes effector activation by increasing the concentration of effectors at the plasma membrane, where additional events facilitate activation or enhance intrinsic catalytic activity. Genes encoding members of the two canonical RAS effector families, BRAF and PIK3CA, are also frequently mutationally activated in human cancers (20% and 12%, respectively, in the COSMIC database; see Supplementary information S1 (table)), which shows the importance of these pathways in driving cancer growth. In addition, cell culture and mouse model 
GTPase
An enzyme that binds and hydrolyzes GTP to GDP. GTP binding and hydrolysis take place within a highly conserved G-domain shared among all GTPases.
Isoprenoid
A class of organic lipid compounds made up of two or more structural units derived from isoprene, a five-carbon hydrocarbon with a branched-chain structure.
Prenylation
The covalent and irreversible addition of hydrophobic 15-or 20-carbon isoprenyl groups to the carboxy-terminus of proteins with an appropriate signal motif. This modification facilitates protein attachment to cell membranes. G12V  G12C  G12S  G12A  G12R  G12F  Other   G12  G13  Q61  Other   G12  G13  Q61  A146  Other   LAC  CRC  PDAC   LAC  CRC  PDAC   NRAS  KRAS  HRAS   35   83   23   3   62   14   12   20   2   94   2  6 2   91  76   27   34   4   a   b   c   1   1  1   30   27   51  45   18   23   12  2  7  2  8  4   44   8   11   2  2  3   <1 (G12L, G12Y, G12E)   <1 (including A146) <1 (G12F, G12W) <1 (G12F, G12L) 1 <1 1 1 studies have established cancer-driving roles for at least four other RAS effectors 1 . In light of the crucial requirement for effector signalling in mutant RAS function, most current efforts to develop RAS-targeted therapies have focused on pharmacological inhibitors of effector signalling, as described below.
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In the following sections, we summarize the progress that has been made in five key approaches to target RAS. We note that, as almost none of these approaches is selective for mutant RAS, additional future strategies that do not rely on selective RAS dependency may be required to enhance the therapeutic index for cancer cells.
Box 1 | Frequency and distribution of RAS mutations in human cancers
The frequency and distribution of RAS gene mutations are not uniform 1, 191 . KRAS is the isoform most frequently mutated (in 86% of RAS-driven cancers), followed by NRAS (in 11% of RAS-driven cancers) and, infrequently, HRAS (in 3% of RAS-driven cancers) (see the figure; COSMIC; see Supplementary information S1 (table) ). Overall, RAS mutations have been detected in 9-30% of all tumour samples sequenced (depending on the database used), with the specific RAS isoform generally differing according to cancer type. In pancreatic ductal adenocarcinoma (PDAC; ~90% of all pancreatic cancers) and lung adenocarcinoma (LAC; 30-35% of all lung cancers) there is almost a 100% frequency of KRAS mutations. In colon and rectal carcinoma (CRC), KRAS is also the predominantly mutated isoform (in 86% of CRC), whereas NRAS mutations are infrequent (in 14% of CRC) and HRAS mutations have not been detected. Conversely, KRAS and NRAS are seen at equivalent frequencies in multiple myeloma, and NRAS is the predominant isoform mutated in cutaneous melanomas (in 94% of cases) and acute myelogenous leukaemias (AML; in 59% of cases). Although rare overall, HRAS mutations are predominant in bladder (in 57% of cases) and in head and neck squamous cell carcinomas (HNSCC; in 86% of cases).
Cancer-associated RAS genes are characterized by single base missense mutations, 98% of which are found at residues G12, G13 or Q61 (see the figure, part a). Whereas G12 mutations are predominant in KRAS and HRAS, Q61
mutations are predominant in NRAS. There are also cancer-type differences in the relative frequency of mutations at these positions (see the figure, part b). In PDAC and LAC, KRAS mutations are found predominantly at G12. In CRC, G12 is also the predominant position (in 75% of cases), but additionally there is a considerable frequency of G13 mutations (in 20% of cases), of mutations at A146, which is a position rarely mutated in other cancers, and, to a lesser frequency, at K117. There are also cancer-type differences in the substitutions seen at a given residue (see the figure, part c); for example, at G12, in PDAC and CRC the predominant substitution is G12D, followed by G12V. By contrast, in non-small-cell lung cancer (NSCLC), the major substitution is G12C, which is rare in PDAC (3%). Direct RAS inhibitors -druggable after all? Direct targeting of RAS has been thought to be a very challenging, if not impossible, task. Although some potential binding sites have been identified using computational approaches 24, 25 , there do not seem to be any deep hydrophobic pockets on the surface of KRAS that would allow tight binding of small molecules. Nevertheless, there have been several attempts to discover small molecules that bind directly to RAS 26 . This section describes these efforts.
Low-affinity inhibitors. One of the first compounds reported, SCH-53239 (FIG. 2) , was designed to compete with GDP for the nucleotide-binding site of RAS 27 . However, a water-soluble analogue, SCH-54292, (FIG. 2) was found by NMR (nuclear magnetic resonance) spectros copy to bind not to the nucleotide binding site but instead to a hydrophobic pocket near the switch II (SII) region of RAS
; the observed intermolecular nuclear Overhauser effect involving I100 and R68 of RAS suggests that the molecule binds with the hydroxylamine located near the magnesium cation 27 . Additional compounds were prepared in which the sugar of SCH-54292 was replaced with a bicyclic moiety on the basis of molecular modelling (bicyclic analogue ;  FIG. 2) ; these compounds inhibited nucleotide exchange similarly to the originally described molecules within this series 28 . Two of these analogues also inhibited RAS-dependent cell growth. However, all of these compounds contain a hydroxylamine, which seems to be crucial for their activity but is not an ideal functional group in a drug molecule owing to its toxicity and poor metabolic stability. Furthermore, these compounds are not very potent.
Box 2 | Regulation of the RAS GDP-GTP cycle
The three RAS genes encode four 188-189 amino acid proteins that share 82-90% overall sequence identity (see the figure; blue vertical lines indicate amino acid non-identity). KRAS encodes two splice variants that result from alternative exon 4 use, which produce proteins with divergent carboxy-terminal sequences. Exons 4A and 4B encode 39 and 38 amino acids, respectively, with 19 identical and 4 conserved substitutions. Uniquely among the RAS isoforms, KRAS4B can be phosphorylated by PKCα at S181. KRAS4A is most similar to the original retroviral KRAS, whereas KRAS4B is the predominant isoform that is expressed in human cells. Residues in the switch I (SI; amino acids (aa) 30-38) region and switch II (SII; aa 60-76) region change in conformation during GDP-GTP cycling. Wild-type RAS proteins bind GDP and GTP with low picomolar affinities. With cellular levels of GDP and GTP at millimolar concentrations, RAS is persistently nucleotide-bound. RAS proteins possess low intrinsic GTP hydrolysis and guanine nucleotide exchange activities, which are regulated and accelerated by GTPase activating proteins (RASGAPs) and guanine nucleotide exchange factors (RASGEFs), respectively. In resting cells, RAS is predominantly GDP-bound. Following growth factor stimulation and activation of RASGEFs, nucleotide binding is destabilized and the nucleotide is released. As the cellular concentrations of GTP are tenfold higher than that of GDP, RASGEFs promote transient formation of RAS-GTP, with RASGAPs returning the protein to the inactive GDP-bound state. RAS that is mutated at G12, G13 or Q61 is impaired in intrinsic and GAP-stimulated GTP hydrolysis activity, which favours the persistent formation of RAS-GTP. 
Fragment-based screening
A method in drug discovery used to find lead compounds, based on initial identification of small chemical fragments that may bind only weakly to the biological target. By combining the fragments, a higher affinity lead compound can be designed.
Another group of compounds that have been reported to noncovalently bind to RAS and to inhibit formation of the RAS-RAF complex was based on the non-steroidal anti-inflammatory drug, sulindac sulphide 29 (FIG. 2) . Sulindac analogues were synthesized and the most potent one, when complexed with the nonhydrolysable GTP analogue, GppNHp, was shown to bind to RAS at the RAF-binding site 30 . In addition, this compound inhibited the RAS-RAF interaction with a median inhibitory concentration (IC 50 ) of 30 μM and decreased the phosphorylation of extracellular signalregulated kinase (ERK), which occurs downstream of RAF activation ( see FIG. 3 for pathway) . The sulindac derivative IND12 selectively inhibited the proliferation of RAS-transformed cells 31 , induced the expression of E-cadherin and increased the level of E-cadherin-bound β-catenin, thereby decreasing invasion 32 . However, none of the sulindac group of compounds is so far potent enough to be a useful drug and it is unclear whether the other off-target activities of sulindac and its derivatives would be problematic.
In a yeast two-hybrid screen for other compounds that would inhibit the RAS-RAF interaction, small molecules (such as MCP1 (FIG. 2) and later derivatives) were discovered that inhibited RAF activation in cancer cells and reversed RAS-transformed phenotypes 33, 34 . Again, the compounds were not very potent. Structural information on how they bind has not yet been obtained but could be useful for improving the potency of these compounds if it becomes available. For Zn-cyclen (FIG. 2) , structural information has been reported on how it binds to RAS and blocks the RAS-RAF interaction 35 , but owing to its lack of selectivity for binding proteins and chelating different metals, Zn-cyclen is not a good starting point for the design of drug-like molecules. Nevertheless, this work revealed that RAS has at least two distinct conformational states when bound to GTP analogues and showed that it could be possible to stabilize one of these conformations to inhibit effector interactions.
GEF inhibitors.
The RAS GTP-GDP cycle is negatively regulated by GAPs and positively regulated by guanine nucleotide exchange factors (GEFs), which facilitate the dissociation of GDP and thereby promote binding of the more abundant GTP moiety
. The most prominent RASGEF is SOS1, which has multiple binding sites for RAS. In addition to the small organic molecules that bind to RAS, a peptide based on the αH helix of the SOS1 RASGEF -the region that forms contacts with RAS (HBS3 peptide (FIG. 2) ) -was found to bind directly to RAS in a cleft near the SI and SII regions 36 . The new peptide was designed to be more water soluble than the SOS1 αH peptide and to have a more helical character. To do this, the hydrogen bond surrogate approach was used, in which the amino-terminal hydrogen bond between the carbonyl of the i th amino acid and the amine of the i+4 th amino acid was replaced with a carbon-carbon bond. This peptide bound to GDP-bound RAS with a dissociation constant (K d ) of 158 μM, inhibited RAS activation and regulated ERK-MAPK (mitogen-activated protein kinase) signalling in cells. Although the reported peptide was not very potent, further optimization of the helical peptide could lead to the development of drug-like molecules, as was recently shown to be the case for stapled helix peptides targeting challenging protein-protein interactions 37 . In 2012, two groups reported on KRAS4B binders that were discovered from fragment-based screening 38, 39 . A group from Genentech, California, USA, identified a compound called DCAI (FIG. 2) , which was shown to bind to a pocket located between the α2 helix and the β-sheet of KRAS, as shown by an X-ray structure Box 3 | Regulating RAS membrane association and subcellular localization RAS proteins are initially synthesized as cytosolic and inactive proteins. All four RAS proteins terminate in a carboxy-terminal CAAX tetrapeptide motif that is comprised of an invariant cysteine residue to which the lipid is attached, followed by two typically aliphatic residues (AA) and the C-terminal residue (X) that contributes to prenyltransferase substrate specificity (see the figure) . The CAAX motif is necessary and sufficient to signal a series of post-translational modifications that enhance the hydrophobicity of RAS, which facilitates membrane association. The first step is catalysed by cytosolic farnesyltransferase (FTase)-mediated covalent addition of a 15-carbon (C15) farnesyl isoprenoid to the cysteine of the CAAX motif, followed by RAS-converting enzyme 1 (RCE1)-catalysed proteolytic removal of the AAX peptide, and finally isoprenylcysteine methyltransferase (ICMT)-catalysed carboxylmethylation of the now terminal farnesylated cysteine. FTase inhibitors (FTIs) prevent all three modifications. All RAS proteins are modified by FTase in cells. However, following FTase inhibition by FTI treatment, KRAS4B and NRAS can be modified instead by the addition of a C20 geranylgeranyl isoprenoid by the related enzyme geranylgeranyltransferase I (GGTase I). The CAAX-signalled modifications alone are not sufficient to promote RAS trafficking and association with the inner face of the plasma membrane. RAS proteins have a second membrane-targeting element that is comprised of either a polybasic amino acid stretch (as in KRAS4B) or cysteine residues that undergo reversible acylation (by palmitoyl acyltransferase (PAT)) and deacylation (by acyl-protein thioesterase (APT)), which add or remove the C16 fatty acid palmitate. PDE6δ is thought to solubilize nonpalmitoylated RAS proteins, thereby promoting their availability for restoration to the plasma membrane. GGTI, GGTase inhibitor; Me, methyl group; PDE6δ, phosphodiesterase 6δ. of the co-complex (FIG. 4a) . DCAI weakly inhibited SOS1-mediated nucleotide exchange (IC 50 = 340 μM) by blocking the interaction between RAS and SOS1 and inhibited RAS activation in cells. Independently, a group from Vanderbilt University, Tennessee, USA, discovered several groups of fragment hits in an NMR-based screen of 11,000 compounds that bind weakly to GDP-bound KRAS. The X-ray structures of several of these hits and of their water soluble analogues bound to KRAS indicated that they all bind to the same pocket: the same site . Structure-activity relationship studies led to the development of a derivative with greater water solubility, SCH-54292. Subsequently, another group used molecular modelling to design a series of sugar-derived bicyclic analogues 28 . On the basis of earlier observations that the non-steroidal anti-inflammatory sulindac showed antitumour activity in Hras-mutant rat mammary carcinomas 224 , the active metabolite sulindac sulphide was evaluated and found to bind to HRAS 29 . IND12 is a sulindac derivative that blocks the growth of RAS-transformed cells 31, 32 . MCP1 was identified in a yeast two-hybrid screen for inhibitors of HRAS binding to full-length CRAF (REF. 34 ). Zn-cyclen selectively binds to and stabilizes the conformational state of RAS that has weak effector-binding affinity 35 . The HBS3 peptide is a mimic of the SOS1 αH helix that interacts with HRAS 36 . DCAI and were identified in fragment-based library screens for KRAS4B-binding molecules 35, 36 . Kobe 0065 was identified in a computer docking screen of a virtual compound library and was selected for its ability to inhibit HRAS-GTP binding to RAF-RAS-binding domains (RBDs) 40 . Kobe 2602 was identified in a subsequent computer-assisted similarity search of 160,000 compounds. A KRAS G12C inhibitor (the Shokat compound) was identified using a disulphide-fragment-based screening approach with GDP-bound KRAS-G12C. SML-8-73-1 covalently binds to KRAS-G12C and occupies the nucleotide-binding site 44 . The nucleotide exchange activator (compound 4) stimulates RAS-GTP formation, but disrupts extracellular signal-regulated kinase (ERK) and phosphoinositide 3-kinase (PI3K) signalling 45 . Nature Reviews | Drug Discovery 
where DCAI binds (FIG. 4b) . This pocket is not readily observed in the ligand-free form of KRAS. Instead, compound binding induces a conformational change in the protein in which Y71 moves out of the way, along with M67 and α2 of the SII region, to create a primary binding pocket and a second nearby cleft 39 . From the structural information obtained from the X-ray data, additional compounds were designed and synthesized with improved affinity (for example, VU0460009, K d = 240 μM) relative to the initial fragment hits, but they were still not very potent. Nevertheless, these compounds inhibited SOS1-mediated nucleotide exchange by blocking RAS-SOS1 complex formation, as shown by a series of NMR experiments 39 . Importantly, detailed structural information on how multiple small molecules bind to KRAS was obtained from these studies. However, as with many other previously reported compounds, the small molecules reported in these two papers bind only weakly to KRAS, and the discovery of analogues with large improvements in affinity is likely to be a very challenging task. Also, even if this could be accomplished, whether compounds with such a mechanism of action would be advantageous in the setting of mutationally active RAS proteins is currently controversial.
Inhibitors of CRAF binding. In another study, using a computer docking screen of a virtual library of compounds, several small molecules were selected for their ability to inhibit RAS-GTP binding to the RAS-binding domain of CRAF (also known as RAF1) (REF. Mammalian target of rapamycin (mTOR) exists as two distinct complexes, mTOR complex 1 (mTORC1; which contains the regulatory-associated protein of TOR1 (RAPTOR)) and mTORC2 (which contains the rapamycin-insensitive companion of mTOR (RICTOR)). Rapamycin and its analogues (also known as rapalogues, which include everolimus, ridaforolimus and temsirolimus) are selective for mTORC1, forming a complex with mTOR and FKBP12. Second-generation mTOR inhibitors are ATP-competitive inhibitors of mTOR kinase activity. Data compiled from ClinicalTrials.gov. CRC, colorectal cancer; ERK, extracellular signal-regulated kinase; GIST, gastrointestinal stromal tumour; HCC, hepatocellular carcinoma; MEK, MAPK-ERK kinase; MEKK, MEK kinase; RCC, renal cell carcinoma.
Electrophile
A reagent attracted to electrons that participates in a chemical reaction by accepting an electron pair in order to bond to a nucleophile. A nucleophile is a reactant that provides a pair of electrons to form a new covalent bond.
Driver
Driver mutations confer a growth and/or survival advantage on cancer cells; they may or may not be required for maintenance of advanced malignancies. This contrasts with passenger mutations, which do not confer such an advantage and therefore do not contribute to cancer development.
In addition, the compounds inhibited colony formation of NIH 3T3 mouse fibroblasts and several different human cancer cell lines in soft agar, blocked the proliferation of HRAS-G12V-transformed NIH 3T3 cells and inhibited tumour growth in a xenograft tumour model in nude mice. On the basis of NMR data, the compounds were postulated to bind to a site near the SII region of RAS in a similar but not identical pocket as the Genentech and Vanderbilt compounds (FIG. 4c) . The Kobe compounds bind onto the surface on the side of the α2 helix. Although the compounds are not very potent, it was suggested that they may function as a scaffold for the discovery of analogues with higher potency and selectivity. However, to be useful starting points for lead optimization, a suitable replacement for the toxic thiosemicarbazide scaffold would have to be found.
Mutant-specific inhibitors. Another interesting study recently described a particularly novel approach for targeting RAS 41 . Shokat and colleagues reported on small molecules that covalently bind selectively to the G12C mutant form of KRAS (KRAS-G12C), which is the most frequent RAS mutation found in non-small-cell lung cancer (NSCLC)
. These compounds were discovered by screening a library of small molecules with GDPbound KRAS-G12C using a tethering approach, followed by the design and synthesis of analogues guided by X-ray structures of co-complexes (FIG. 4d) . The compounds were found to bind to a pocket between the α2 and α3 helices, on the other side of the SII region from the Genentech and Vanderbilt compounds, but at a site similar to where SCH-54292 was postulated to bind to KRAS on the basis of NMR data. As predicted, these compounds blocked SOS1-mediated nucleotide exchange and decreased the binding of RAS to both BRAF and CRAF. Interestingly, they also seemed to selectively kill cancer cells harbouring the G12C mutation (FIG. 2) . Lung cancer aside, the G12C mutation is found in only a small subset of cancers compared with other KRAS mutations (BOX 1) and it may be difficult to selectively target other commonly found mutations. However, this work shows that it is possible to selectively target RAS-G12C. This could result in the development of compounds with low toxicity, providing that small molecules could be discovered that do not bind to other cysteine-containing proteins. In other studies aimed at covalent attachment to cysteine-containing proteins, compounds lacking the electrophile that forms the irreversible bond typically bind very tightly to the protein 42, 43 . However, for the KRAS inhibitors in this study, fragments lacking the electrophile do not seem to bind to KRAS-G12C, which suggests that it might be difficult to achieve the necessary selectivity.
Gray and co-workers have also targeted KRAS-G12C. They prepared a GDP analogue with an attached electrophile (SML-8-73-1) that could covalently bind to the cysteine of the G12C mutant form of KRAS 44 . Although small molecules targeting the guanine nucleotidebinding site have been disregarded on the basis of the picomolar affinity of GTP and GDP to KRAS and their high intracellular concentration, SML-8-73-1 was shown to covalently bind to KRAS-G12C even in the presence of 1 mM concentrations of GDP and GTP. In addition, a cell-permeable analogue was shown to attenuate the downstream phosphorylation of AKT and ERK and to have antiproliferative effects in several cell lines 44 . Despite the many attempts to directly interfere with KRAS that have been published so far, KRAS still remains a very challenging target. Although some progress has been made in the identification of different compounds that weakly bind to RAS, the binding affinity of these early-stage compounds would have to be markedly improved for them to be useful drugs. In principle, this might be accomplished by linking these molecules together, providing that the linked compounds had drug-like properties. Alternatively, a different approach may be required, such as the targeting of a RAS-protein interface in which more suitable binding pockets may be present. In this regard, small molecules such as nucleotide exchange activator compound 4 (FIG. 2) have been identified that bind to a hydrophobic pocket in SOS1 adjacent to the SII region of RAS, when SOS1 is in the RAS-SOS1-RAS complex 45 . These compounds were shown to increase the rate of SOS1-catalysed nucleotide exchange and, as expected, to increase the levels of RAS-GTP. However, paradoxically, they cause a biphasic response in the MAPK pathway with inhibition of ERK phosphorylation at high compound concentration, and they inhibit PI3K signalling as shown by a decrease in AKT phosphorylation. These compounds decrease cell proliferation and anchorage-independent growth and suggest another possible approach to target RAS signalling for the treatment of RAS-driven tumours.
Altering RAS localization -back to the future? FTIs. Although FTIs are not effective against the RAS isoforms that are most commonly mutated in human cancers, there is continued discussion as to whether they can still be an effective therapeutic approach for HRASmutant cancers 46 such as thyroid, bladder, head and neck, and skin cancers (BOX 1; TABLE 1). However, even in these cancers, the HRAS mutation frequency is low and the driver function of HRAS, and hence the potential therapeutic value of HRAS-targeted drugs, remains to be vigorously evaluated. As the future of cancer treatment is personalized medicine and full-exome sequencing, if HRAS is ultimately validated as a driver of cancer, then a rigorous assessment of whether HRAS-mutant cancers are responsive to FTIs should be carried out.
The disappointing clinical outcome of FTIs in KRASmutant cancers has decreased interest in the further pursuit of strategies that target RAS membrane association 4 . Thus, although observations from genetic studies in a KRAS-G12D-driven lung cancer mouse model suggested that combination treatment strategies that concurrently block both FTase and GGTase I can be effective and might not be overtly deleterious 47 , there remains considerable caution and lack of interest in this approach. This lack of interest is partly derived from the perception that concurrent inhibition of both enzymes, which collectively may have up to 300 substrates 4 , will be limited by serious toxicity in normal tissues -a point which was not addressed by the genetic studies cited above. Another therapeutic approach that targets the farnesyl modification is the use of salirasib (S-farnesylthiosalicylic acid), which functions as a mimetic of the C-terminal S-farnesyl cysteine modification of RAS. The specific consequences of salirasib treatment on RAS function are varied and include decreased plasma membrane association, decreased RAS-GTP levels and protein stability, and decreased effector signalling [48] [49] [50] . Salirasib can also impair the activities of other farnesylated proteins (for example, RAS homologue enriched in brain (RHEB)) 51 and mammalian target of rapamycin (mTOR), through a mechanism that is not clearly understood 52, 53 . On the basis of positive preclinical results in pancreatic cancer mouse models 54, 55 , a clinical trial was carried out in patients with pancreatic cancer 56 . Although there were some long-term survivors, the main conclusion that could be definitively reached was that the treatment was well tolerated. The number of patients was, unfortunately, too small to determine whether a significant clinical benefit was gained and whether KRAS function was effectively perturbed. Further clinical evaluation is warranted, but a better understanding of the key mechanisms of action of salirasib and accurate biomarkers to monitor target inhibition are also needed.
Inhibitors of RCE1 and ICMT.
Although there has been some interest in developing inhibitors of the two other CAAX-signalled RAS processing enzymes, RASconverting enzyme 1 (RCE1; also known as CAAX prenyl protease 2) and isoprenylcysteine carboxylmethyltransferase (ICMT; also known as protein-S-isoprenylcysteine O-methyltransferase) (BOX 3) , concern that they are probably also required for the function of other proteins that have crucial roles in normal cell physiology has limited discovery efforts; for example, the 19 ICMT substrates in the CXC-terminating RAB family of small GTPases are crucial for regulating vesicular transport. Thus, pharmacological inhibition of either RCE1 or ICMT activity will almost certainly affect the functions of many proteins in addition to RAS, and consequently normal tissue toxicity may well be a limitation for these two targets.
In addition, although earlier studies in Rce1-or Icmtdeficient mouse embryonic fibroblasts (MEFs) revealed impairment in HRAS-mediated transforming activity, subsequent studies found more complex consequences of the loss of these enzymes; for example, Rce1 ablation concurrent with KRAS-G12D activation in mouse haematopoietic cells enhanced myeloproliferative disease 57 . By contrast, Icmt ablation in the same mouse model reduced myeloproliferative disease 58 . However, Icmt ablation concurrent with KRAS-G12D activation in the pancreas caused increased pancreatic intraepithelial lesion formation and accelerated neoplastic progression 59 . One explanation for these results is that both RCE1 and ICMT may have up to 300 CAAXterminating substrates in addition to RAS and that these substrates may be differentially sensitive to enzyme inhibition, depending on the context. Furthermore, although cell-active small molecules have been identified and characterized [60] [61] [62] , potent and selective pharmacological inhibitors of RCE1 and ICMT that are suitable for in vivo analyses have not been identified so far.
Inhibiting palmitoylation and depalmitoylation.
Another lipid modification that has attracted some interest is palmitoylation. Modification by the fatty acid palmitate is essential for the plasma membrane association and function of HRAS and NRAS, and probably KRAS4A. These RAS isoforms are reversibly and covalently modified by one or two palmitoyl fatty acids on cysteines immediately upstream of the CAAX motif. Studies with nonpalmitoylated variants of HRAS and NRAS support the importance of this modification in RAS-driven oncogenesis 63, 64 . One human palmitoyl acyltransferase (a complex of DHHC9 and GCP16) has been described as having activity towards HRAS and NRAS 65 . However, as KRAS4B is not palmitoylated, this approach will not be useful for the majority (85%) of RAS-mutant cancers. Another approach has been suggested as a result RAS is represented as a molecular surface: the ligands are in stick models with yellow carbon atoms and the nucleotides are in stick models with tan carbon atoms. The switch I region is in blue and the switch II region is in purple. a | X-ray structure of KRAS-G12V-phosphomethylphosphonic acid guanylate ester (GCP) bound to DCAI (Protein Data Bank (PDB) 4DST) 38 . b | X-ray structure of KRAS-G12V-GDP bound to VU0460009 (REF. 39 ). c | NMR-derived structure of KRAS-T35S-GNP bound to Kobe 2601 (PDB 2LWI) 40 . d | X-ray structure of KRAS-G12C-GDP bound to the Shokat compound (PDB 4M22) 41 .
of the dynamic acylation and reacylation cycle of RAS, wherein depalmitoylation, perhaps counter-intuitively, promotes RAS redistribution to membrane sites where it is active [66] [67] [68] . Thus, depalmitoylation inhibitors have been suggested as a means of inhibiting RAS membrane association and function 69 . Given that there are 24 known mammalian palmitoyl acyltransferases 70 , it is unclear whether DHHC9-GCP16 is the only member with activity towards RAS proteins, how selective it is for RAS and whether DHHC9-GCP16-selective inhibitors can be developed. It has also not yet been definitively shown whether the observed cellular consequences of depalmitoylation inhibitors are due to inhibition of RAS depalmitoylation. These issues, together with the potential for off-target activities of these inhibitors on non-RAS substrates, are concerns that currently diminish enthusiasm for this therapeutic approach.
Inhibitors of other post-translational modifications.
Other post-translational modifications that can regulate the subcellular localization of RAS and/or effector interactions have also attracted interest as possible directions for RAS-targeted drug discovery. In particular, a classical protein kinase C, PKCα, catalyses phosphorylation of KRAS4B at S181 within the C-terminal polybasic sequence. This phosphorylation causes RAS to dissociate from the plasma membrane and to move to endomembranes 71 , where it interacts with inositol triphosphate (InsP 3 ) receptors on the endoplasmic reticulum (ER). This converts KRAS4B from a growthpromoting to a growth-suppressing protein, in a B cell lymphoma-X L (BCL-X L )-dependent manner 72 . The InsP 3 interaction blocks the ability of BCL-X L to potentiate the InsP 3 -regulated flux of calcium from the ER to the mitochondria, which is required for efficient cell survival. Whether this process can be exploited for anticancer therapy by promoting KRAS4B phosphorylation on this residue is an intriguing but unrealized possibility. This idea is supported by the findings that the PKC agonist bryostatin 1 can cause KRAS4B phosphorylation and translocation to endomembranes where it drives growth suppression, and that mouse tumour xenograft growth was impaired by bryostatin 1 treatment in an S181-dependent manner 71 . Bryostatins have been shown to be well-tolerated in vivo and have antitumour activity 73 . One obvious concern is that PKCs have numerous substrates and, therefore, pharmacological approaches to activate PKC will probably have considerable consequences that are unrelated to RAS phosphorylation. Surprisingly, in contrast to these studies, fundamentally similar analyses by another group reached the opposite conclusions, suggesting instead that S181 phosphorylation is required for KRAS4B-mediated cancer growth 74 . A possible basis for these opposing conclusions has not been addressed.
Another intriguing target is endothelial nitric oxide synthase (ENOS)-catalysed nitrosylation. This posttranslational modification at C118 causes activation of wild-type RAS proteins and may promote activities that are required for cancer growth driven by mutant KRAS 75 . Evidence supporting ENOS as a possible therapeutic target comes from mouse model studies in which genetic ablation of Nos3 (the gene encoding ENOS) in the pancreatic cancer-prone Kras G12D ;Trp53 R172H mice (also known as KPC mice) prolonged survival 76 . Treatment with the ENOS-preferential small-molecule inhibitor N(G)-nitro-l-arginine methyl ester (L-NAME) also impaired the growth of human pancreatic cell line xenografts and modestly increased survival in KPC mice 76 .
A different approach to impairing RAS membrane association was suggested following the discovery of proteins that selectively recognize the farnesylated forms of RAS. Of these, phosphodiesterase 6δ (PDE6δ) has attracted particular interest. PDE6δ, which has a role in photoreceptor signalling, interacts with and regulates the trafficking of the PDE6 complex, which comprises both farnesylated and geranylgeranylated subunits 77 . PDE6δ can also recognize KRAS4B and other prenylated proteins and can facilitate their trafficking to membrane compartments 78 
. Palmitoylation of HRAS, NRAS and KRAS4A prevents the recognition of these proteins by PDE6δ 78 . Deltarasin, a small molecule that inhibits the binding of PDE6δ to KRAS4B, was recently shown to impair the accumulation of KRAS4B on the plasma membrane and to reduce the growth of KRAS-mutant tumour cells 79 . Although these findings are intriguing, discrepancies regarding the degree of KRAS4B dependency on PDE6δ to drive cancer growth and whether PDE6δ function is crucial for CAAX-terminating proteins that are modified by geranylgeranylation will need to be resolved in order to determine the potential therapeutic value of PDE6δ-targeted inhibitors 80 . Finally, additional post-translational modifications of RAS that modulate RAS function include monoubiquitylation of HRAS 81 and of KRAS
82
, polyubiquitylation of KRAS 83 and acetylation of KRAS4B 84 . However, the enzymology of these modifications, the importance of their low stoichiometry and their potential value as therapeutic targets remain unresolved.
Inhibiting RAS effectors -our best bet? There are at least 11 RAS effector families that have been identified so far; mutation data and functional studies have validated that at least six of these contribute to RASdependent cancer initiation and/or maintenance 23, 85 . The RAF serine/threonine kinases (ARAF, BRAF and CRAF) are arguably the most important effectors of mutant RAS-dependent cancer growth, as they have a key driver role in RAS-mediated oncogenesis 86, 87 . The frequent mutational activation of BRAF (see Supplementary information S1 (table)) and the infrequent co-occurrence of this mutation with RAS mutations also provides compelling evidence that RAF has a driver role in RAS-mutant cancers.
RAF−MEK−ERK inhibitors.
The only well-validated substrates of RAF are the highly related dual specificity protein kinases MEK1 and MEK2 (which have 80% identity), and the only well-validated MEK1 and MEK2 substrates are the highly related ERK1 and ERK2 serine/ threonine kinases (which have 86% identity). These findings initiated the early perception that this protein
Allosteric regulation
Regulation of an enzyme by binding of a molecule at a site that is not directly involved in its enzymatic activity. This binding often results in a conformational change that then enhances or decreases enzyme activity.
kinase cascade is a simple, linear and unidirectional signalling pathway. However, it is now well-established that the RAF−MEK−ERK cascade is at the centre of a complex signalling network that has multiple inputs and outputs, feed-forward and feedback mechanisms, and multiple scaffold proteins that dynamically regulate signalling and ERK activity 88 .
At least 11 pharmacological inhibitors of RAF kinases have reached clinical evaluation, with four approved for use by the US Food and Drug Administration (FDA) (FIG. 3) . Although sorafenib was originally developed as a RAF inhibitor 89 , the antitumour efficacy of this multikinase inhibitor is probably due to its ability to block tyrosine kinases that are involved in tumour angiogenesis, such as members of the vascular endothelial growth factor receptor (VEGFR) family 90 . Two ATP-competitive RAF inhibitors, vemurafenib and dabrafenib, have been approved for use in BRAF-mutant metastatic melanoma 91 . Paradoxically, when these RAF inhibitors were evaluated in RAS-mutant cancer cells, activation -rather than inactivation -of ERK was seen [92] [93] [94] , as had been documented years earlier with a preclinical agent 95 . RAF dimerization, which is mediated by active RAS, causes activation of RAF, and these first-generation RAF inhibitors promote RAF dimerization 96, 97 . This accounts for the RAF inhibitor-induced development of benign skin tumours, including keratoacanthomas, and of squamous cell carcinomas of the skin in individuals with mutant RAS. Both second-generation RAF inhibitors that show pan-RAF activities and/or do not promote RAF dimerization, as well as inhibitors designed to block dimerization, are now under consideration; these may prove to be more efficacious in the long run 98 . (FIG. 3) , with trametinib (GSK112021) recently approved by the FDA for BRAF-mutant metastatic melanoma. The majority of these inhibitors function, via allosteric regulation, as non-ATP competitive inhibitors of MEK1 and MEK2 and consequently are highly selective. Although MEK inhibitors have been effective against BRAF-mutant melanoma, they have only been partially effective in RAS-mutant cancers and human tumour cell lines 99 and in mutant Ras-driven mouse models of cancer 100 . Interestingly, the activation state of MEK and the mechanisms by which it is activated in RAS-versus BRAF-mutant cancers are distinct, and one recent study suggested that this influences the response to specific MEK inhibitors 101 . For example, MEK inhibitors that function similarly to GDC-0623 and G-573 are likely to be more effective in RAS-mutant cancers because they form a strong hydrogen bond with MEK S212 and block MEK feedback phosphorylation by RAF, whereas those that function similarly to cobimetinib (GDC-0973) are better at inhibiting active, phosphorylated MEK 101 .
At least 15 MEK inhibitors have reached clinical evaluation
The dual RAF−MEK inhibitor RO5126766 can function in a similar manner 102 . Innate or acquired resistance of RAS-mutant cancer cells to MEK inhibitors can occur by upregulation of receptor tyrosine kinase activity 103 or by amplification of upstream activators 104 that enhance flux through the pathway to increase ERK activity above the 80% suppression threshold that is needed to achieve a therapeutic response 105 . As innate or acquired mechanisms of resistance to RAF or MEK inhibitors are often due to reactivation of ERK, one obvious approach is to use an ERK inhibitor. Three ERK inhibitors have entered clinical evaluation (FIG. 3) and an analogue of one (MK-8353; also known as SCH9000353) has been characterized in preclinical models 106 . However, similarly to MEK inhibitors, ERK inhibitors also block ERK feedback phosphorylation and inactivation of RAF, which leads to enhanced MEK activation. Combined inhibition of the RAF−MEK−ERK cascade at multiple nodes may provide more effective inhibition as well as reduced toxicity.
PI3K−AKT−mTOR inhibitors.
The second-best validated class of RAS effectors is comprised of the p110 catalytic subunits (α-, γ-and δ-subunits) of class I PI3Ks. The frequent mutational activation of PIK3CA (which encodes p110α; mutated in 12% of tumours according to the COSMIC database) and inactivation of the phosphatase and tensin homologue (PTEN) tumour suppressor support the idea that PI3K has a driver role in RAS-dependent cancer growth. As PI3K activity can also be modulated by non-RAS mechanisms, Downward and colleagues 107, 108 applied an innovative approach to assess the importance of RAS-dependent PI3K activation alone. They generated mice with a germline mutant Pik3ca allele encoding a p110α variant with point mutations in the RAS-binding domain, which prevents RASmediated activation but retains non-RAS-dependent activities 107, 108 . Near-complete ablation of tumour initiation and partial regression of tumour growth was observed in a Kras-driven mouse model of lung cancer, which indicates that KRAS requires p110α in this context. A similar partial reduction in tumour growth was seen following pharmacological inhibition of p110α. The importance of continued PI3K activity in tumour maintenance was also shown in KRAS-mutant human tumour cells, in which activated p110α was able to substitute for the loss of mutant KRAS to maintain tumour growth 9 . Although the results from mouse model analyses provide a compelling argument that PI3K inhibition may be an effective RAS-targeted strategy in some settings, there is also evidence that PI3K is not always a key RAS effector. Pharmacological inhibition of this pathway in Kras-driven mouse lung cancers did not effectively block tumour growth 100 . Furthermore, KRAS silencing in KRAS-mutant colorectal cancer cell lines did not reduce activation of the PI3K effector AKT, although it effectively reduced ERK activation 109 ; rather, increased receptor tyrosine kinase signalling accounted for the maintenance of AKT activation 109 . Finally, in contrast to the non-overlapping BRAF and RAS mutations seen in human cancers, PIK3CA and RAS mutations are often seen together. Although correlative, this pattern suggests that mutated RAS alone may not potently activate PI3K signalling. Nevertheless, targeting PI3K−AKT signalling in RAS-mutant cancers, particularly in combination with other pathways, may have therapeutic value.
At least 53 inhibitors of PI3K−AKT−mTOR signalling are under clinical evaluation (FIG. 3) . As monotherapies, these have shown disappointing activity against RAS-mutant cancers in preclinical and clinical evaluation. However, in mouse models, potent synergistic activity with inhibitors of ERK−MAPK signalling has been seen 100 . There are numerous clinical trials evaluating the combined inhibition of RAF and PI3K effector signalling 110 .
RAL inhibitors.
RALGEFs constitute the third-best validated effectors of RAS-driven cancer growth 111, 112 . Mice that are deficient in RAL guanine nucleotide dissociation stimulator (RALGDS), which is one of the four RA domain-containing RALGEFs, were viable but showed reduced carcinogen-induced mutant Hras-driven skin tumour formation 113 . Another RALGEF, RGL2, was found to be overexpressed in KRAS-mutant colorectal cancer cell lines, and short hairpin RNA (shRNA)-mediated suppression of RGL2 reduced RAL-GTP levels and impaired cell growth in vitro 114 . RALGEFs are activators of two related isoforms, RALA and RALB, and shRNA-mediated silencing of RALA and/or RALB in KRAS-mutant pancreatic cancer cell lines impaired cell growth. Interestingly, in the majority of cell culture studies, RALA and RALB have distinct roles in cancer cell behaviour; for example, RALA but not RALB was found to be necessary for the tumorigenic growth of pancreatic cancer cell lines, whereas RALB was important for invasion in vitro and experimental metastasis in vivo 115 . By contrast, in conditional tissue-specific genetic ablation studies, loss of both RALA and RALB was required to reduce RAS-driven lung or skin tumour growth 116 . These findings may reflect different roles for RAL GTPases in tumour initiation and progression versus maintenance, or cancer-type differences.
Similarly to RAS, the RAL GTPases are not considered to be tractable drug targets. Therefore, current directions for therapeutic inhibition of RAL involve protein kinases that either modulate RAL subcellular localization and effector use or that function as downstream effectors. Analogous to PKCα phosphorylation of KRAS4B, Aurora A and PKCα phosphorylate C-terminal serine residues in RALA and RALB, respectively, which promotes their driver functions in cancer growth [117] [118] [119] [120] . RALB effector signalling can lead to activation of the serine/ threonine kinase TANK-binding kinase 1 (TBK1) or the mTORC1 serine/threonine protein kinase complex 121, 122 . Thus, protein kinase inhibitors may provide promising directions for blocking aberrant RAL GTPase signalling downstream of RAS.
RAC1 inhibitors.
The fourth-best validated effector of RAS-driven cancer growth is the RAC1 small GTPase 123 . RAS can activate RACGEFs and subsequently RAC1 through direct effector binding (for example, T lymphoma invasion and metastasis-inducing protein 1 (TIAM1)) 124 or indirectly through PI3K activation (for example, phosphatidylinositol 3,4,5-trisphosphate-dependent RAC exchanger 1 protein (PREX1)) 125 . The importance of RAC1 as a crucial driver of cancer growth is supported by the recent identification of activated RAC1 mutations in cutaneous melanomas 126, 127 . That inhibition of RAC1 may have a therapeutic benefit in RAS-mutant cancers is supported by mouse model studies in which genetic ablation of Rac1 function impaired the initiation of mutant Kras-driven lung or pancreatic cancers 128, 129 . However, similarly to RAS, RAC1 is a small GTPase and therefore whether direct RAC1 inhibitors can be developed is still unclear. One small-molecule inhibitor of RAC1 activation by RACGEFs has been described 130, 131 , which suggests that it may be feasible to develop inhibitors of RAC1 activation. Alternatively, similarly to current approaches for RAS, inhibitors of RAC1 effector signalling may be more tractable. However, of the many RAC1 effectors that have been identified, which of them are essential drivers of RAC1-dependent growth remains unanswered. The PAK1 serine/threonine kinase, which is found to be overexpressed in many cancers, is one possibility. Genetic ablation of Pak1 suppressed Kras-induced lung tumour formation in mice, and pharmacological inhibition of PAK1 phenocopied the loss of Pak1 function 132 . In addition, the p110β isoform of PI3K was recently found to function as an effector for RAC1 rather than for RAS 133 , which provides another candidate effector of RAC1-dependent cancer growth.
Although other RAS effectors (for example, phospholipase Cε and RA domain-containing protein 1 (RASSF1)) have roles in cancer cell proliferation, these may not function as drivers of RAS-dependent cancer growth and, hence, their therapeutic value is unclear 134 . In summary, although effector inhibition seems to be the most promising RAS-targeted strategy so far, considerable challenges remain. Firstly, inhibition of any one effector pathway is complicated by compensatory mechanisms, which necessitates inhibition at multiple points. Secondly, because multiple effectors have driver roles, concurrent inhibition of multiple pathways will be needed. This has prompted both preclinical and clinical evaluation of combining inhibitors of components of the RAF and/or PI3K effector networks. However, as the combinations are expanded to achieve more effective blockage of effector signalling, the offsetting increase in normal cell toxicity may tip the balance and cause loss of the therapeutic window. How to strike this balance is another important question for the future.
Synthetic lethals -needles in the haystack?
One possible approach to increasing therapeutic selectivity for cancer cells would be to identify potential 'Achilles' heel' targets that have synthetic lethal interactions with the RAS oncogene; that is, genes for which the loss of function would be lethal only in the presence of mutated RAS (FIG. 5) . Widespread observations of synthetic lethality in lower organisms suggested that genetic buffering, in which one or more genes can functionally compensate for mutations in another gene, may be common 135 
, and
Achilles' heel A deadly weakness or vulnerable point whose targeting can lead to the downfall of an otherwise strong entity (e.g., protein).
Synthetic lethality
A genetic interaction whereby two otherwise non-lethal genetic mutations lead to cell death. Nature Reviews | Drug Discovery 136 . This approach could be particularly useful in situations in which pharmacological action cannot be taken against the oncogenic mutations themselves, as in the case of RAS mutations.
The existence of oncogene-specific synthetic lethal interactions is supported by the fact that oncogenic mutations lead to prominent phenotypic changes in cancer cells, collectively known as the 'hallmarks of cancer' -in these circumstances, normal cellular pathways are co-opted, either directly or indirectly, to support the malignant growth of cancer cells. This often manifests in one of two ways. Firstly, oncogenic transformation leads to elevated cellular stress (also known as oncogenic stress), which requires the cancer cell to activate cellular stress-relief pathways for survival. Secondly, cancer cells often adapt their signalling pathways and alter their metabolic flux to support proliferation and this requires compensatory changes in pathways that are not directly downstream of the driver oncogene. These 'non-oncogene addictions' collectively constitute potential synthetic lethal interactions (FIG. 5) that may be exploitable for therapeutic intervention 139 . The potent effect of poly(ADP-ribose) polymerase (PARP) inhibitors in breast cancer susceptibility gene (BRCA)-mutant cancers is an example of exploiting synthetic lethality; BRCA1 and BRCA2 mutations result in deficiencies in DNA homologous recombination repair and render the cell particularly dependent on PARP-mediated non-homologous end-joining DNA repair for genomic stability.
Screen results.
Several studies have applied RNAi screens in human cancer cell lines to identify synthetic lethal interactors with the KRAS oncogene (reviewed in REF. 140 ). Screens done using a variety of small interfering RNA (siRNA) and shRNA libraries, both in a well-by-well or a pooled format, have confirmed that many KRAS-mutant cell lines are indeed functionally addicted to the KRAS oncogene. These screens have identified a wide range of genes that have synthetic lethal interactions with mutant KRAS (TABLE 2) . These genes encode proteins that can be categorized into several cellular processes: those associated with the cell cycle and mitosis (such as survivin (also known as BIRC5), targeting protein for XKLP2 (TPX2), PLK1 and anaphase promoting complex, also known as the cyclosome (APC/C)), those associated with cell survival (Wilms' tumour protein homologue 1 (WT1) and BCL-X L ), those associated with collaborative transcriptional programmes (GATA-binding protein 2 (GATA2) and SNAIL2 (also known as SNAI2)), and those associated with parallel growth and survival signals (TBK1 and TAK1 (also known as NR2C2)) (FIG. 5) . Although the roles of mutant KRAS in cell proliferation, genomic instability and apoptosis have been previously described 141 , the findings of KRAS dependency on kinases such as TBK1 (REF. 129) and transcription factors such as GATA2 (REF. 142) indicate that additional cellular pathways are involved in supporting the viability of KRAS-transformed cells. So far, none of the synthetic lethal interactors has been found to be equal or superior to KRAS itself at discriminating KRAS-mutant and KRAS-wild-type cells. The overlap among the 'hits' from different KRAS synthetic lethal screens has generally been small, although proteasome subunits have been identified in three screens [143] [144] [145] . The lack of considerable overlap can be attributed to several factors. The patterns of nononcogene addictions in the presence of the common KRAS driver oncogene -and therefore the synthetic lethal interactions identified -may be context-dependent. Cancer cells harbour multiple oncogenic mutations 2 and secondary mutations could alter the patterns of genetic dependency 146, 147 . In addition, tumours arising from different organs show distinct lineage phenotypes despite harbouring similar oncogenic mutations 148 ; thus, KRAS mutations could drive genetic dependencies in a tissue-specific manner. All of these factors could cooperate with KRAS in determining the landscape of nononcogene addictions in cancer cells. If the landscape is indeed this fragmented, 'universal' KRAS synthetic lethal interactors might be difficult to identify.
Improving the screen.
Although the first generation of KRAS synthetic lethal screens has revealed interesting biological information about KRAS-mutant cancers, the findings have suffered from several technical limitations that have reduced confidence in the applicability of the results to future drug development. The most prominent of these limitations is the lack of library validation, which could contribute to high false-negative rates in the screen. In addition, library penetrance (that is, the number of siRNAs and shRNAs that effectively knock down a given gene) is highly variable among the different libraries, which could also lead to high and variable false-negative rates. A new generation of libraries with multiple validated siRNAs and shRNAs per gene would considerably improve the penetrance of the screen and would also make it easier to rule out off-target effects, which would thereby decrease the false-positive rate. Furthermore, a validated library is likely to be more widely adopted by the research community, which would make crossstudy comparisons easier. Finally, as a result of cost and feasibility issues, first-generation synthetic lethal screens were typically carried out using either KRAS-isogenic cell lines or a small panel of KRAS-mutant and KRAS-wildtype cell lines. Although isogenic cell lines can be useful for identifying the effect of individual oncogenes, care should be taken to recognize their limitations; for example, introduction of mutant KRAS into wild-type cells may not necessarily confer KRAS oncogene addiction. Conversely, loss of mutant KRAS might force any surviving cells that are now KRAS-wild-type to compensate by upregulating other pathways to which they then become addicted, such as the pathways associated with the transcriptional co-activator YAP1 (REFS 149, 150) .
Efforts to screen large panels of cancer cell lines are underway, which should more thoroughly take into account the heterogeneity among KRAS-mutant cell lines that occurs as a result of different lineages and coexisting mutations 151, 152 . Indeed, a recent siRNA analysis of a large number of lung cancer cell lines revealed that the majority of genetic dependencies are 'private' to individual cell lines and only a minority of genetic dependencies are shared 'publicly' among many cell lines 147 . Screening a very large cell line collection such as the Cancer Cell Line Encyclopedia (CCLE) 153 would also be useful to determine the landscape of KRAS synthetic lethality in a context-dependent manner. Finally, all currently described synthetic lethal screens were conducted in vitro using anchorage-dependent proliferation or viability as the readout. Second-generation synthetic lethal screens could benefit from other assay formats such as in vitro anchorage-independent colony formation assays or in vivo xenograft tumour assays that better interrogate the tumorigenic capability of the KRAS oncogene. Both of these types of assays have been successfully adapted for high-throughput screening [154] [155] [156] [157] . However, these assays are likely to be less robust and they require considerable effort; hence, knockdown-validated shRNA libraries would be particularly useful in these screens.
Compared to in vitro viability assays of cells cultured on plastic, in vivo screening has the benefit of providing a more physiological setting and the potential to reveal genes that are required for tumour growth rather than for cancer cell proliferation in vitro. Pooled shRNA libraries have been successfully applied in vivo both for enrichment screens to identify tumour suppressor genes [158] [159] [160] and for dropout screens to identify tumour-essential genes 155, 157 . By using syngeneic mouse cancer cells 155, 160 , in vivo screening also has the potential to address the roles of the microenvironment and immune interactions in tumour growth.
From a therapeutic point of view, targeting synthetic lethality should provide a work-around solution to an undruggable oncogene. However, KRAS synthetic lethal interactors from the first generation of screens may not be ideal candidates for drug discovery: targeting the cell cycle machinery could lead to considerable toxicity in normal proliferating tissues, whereas transcription factors such as GATA2 are themselves undruggable and require indirect targeting strategies 161 . Although serine/threonine protein kinase 33 (STK33) was initially proposed to be a druggable target in KRAS-mutant cells 144 , subsequent studies have found that neither genetic nor pharmacological inhibition of STK33 selectively inhibited the growth of such cells 162 . Genetic and pharmacological evaluations of TBK1 found no consistent requirement for TBK1 in the growth of KRAS-mutant tumour cell lines in vitro 163 , although combined TBK1 and MEK inhibition led to partial regression of lung tumours in mice with mutations in both Kras and Trp53 (REF. 164 ). This result highlights a limitation of high-throughput screening -hits must be rigorously validated. Further effort is therefore necessary to identify better synthetic lethal candidates for drug discovery. However, given the uncertain success of current strategies for targeting KRAS effector signalling, synthetic lethal screening may still be a valuable approach to broaden therapeutic approaches that are orthogonal to RAS pathway inhibitors. One recent study determined that combined targeting of both MEK and BCL-X L led to synthetic lethality and improved therapeutic efficacy compared with loss of either protein alone, with tumour regressions obtained in both KRAS-driven xenografts and in a genetically engineered mouse model of lung cancer 165 .
An exciting recent development in genetic screening is the adaptation of the bacterial type II CRISPR-Cas9 (clustered regularly interspaced short palindromic repeatsCas9) system for genome editing in mammalian cells 166 . In this method, a short 20-nucleotide single guide RNA (sgRNA) sequence directs the RNA-dependent DNase Cas9 to cleave any target gene bearing sequence homology to the sgRNA. Imprecise double-strand DNA repair through non-homologous end-joining subsequently leads to insertion or deletion mutations that knock out gene expression. Similarly to RNAi, CRISPR relies on short-length sequence homology and therefore could suffer from similar off-target effects. However, in contrast to RNAi, which produces various degrees of hypomorphic phenotypes, CRISPR generates true null phenotypes when properly designed, thus vastly improving library penetrance. Pooled CRISPR libraries have been used for genetic screens in human cell lines 167, 168 and this approach is likely to provide an orthogonal, and potentially superior, alternative to RNAi screens in the search for mutant RAS synthetic lethal interactions. A recent CRISPR screen in a melanoma model identified both previously validated and novel genes, the loss of which promoted resistance to the BRAF inhibitor vemurafenib 167 . Metabolic dependency -ready for prime-time?
In order to meet the increased biosynthetic demands of a growing tumour, cancer cells alter their metabolism. Metabolic changes were first observed in pioneering research in the 1920s by Otto Warburg 169 , when he showed that tumour cells take up excess glucose and produce lactate even in the presence of oxygen (in a process known as aerobic glycolysis or the Warburg effect). These metabolic adaptations, including the Warburg effect, are now recognized as one of the hallmarks of cancer 138, 139 . One of the major requirements of tumour cells, given their deregulated proliferation, is the need to increase biomass. Thus, there is a shift towards anabolic metabolic processes to produce building blocks such as amino acids, nucleic acids, lipids and cofactors such as NADPH for redox balance and reductive biosynthesis [170] [171] [172] . Although much is known about the altered metabolism of tumour cells, more recent work has shown that many of the metabolic changes seen in these cells are brought about on a molecular level by oncogenes and tumour suppressor genes [173] [174] [175] . Indeed, oncogenic RAS has been shown to be a key player in promoting such metabolic rewiring, although the specifics may differ depending on tumour type and genetic context 15, 176 . Importantly, many of the metabolic changes driven by oncogenic RAS become crucial for tumour maintenance and thus become attractive therapeutic targets in their own right. In addition, because they are not dependent on oncogenic RAS, normal tissues often do not have the same reliance on such pathways and therefore there is potential for a tractable therapeutic index. The fact that metabolic reactions are enzyme-mediated also presents the opportunity to inhibit their catalytic activity with small molecules. In this section, we review the metabolic changes that are driven by oncogenic RAS and explore the therapeutic possibilities of targeting these pathways in various tumour types.
Metabolic recycling. One of the convergent themes in the metabolism of RAS-driven cancers is that they have developed a reliance on several mechanisms to either recycle intracellular fuel sources or to scavenge extracellular constituents to meet their metabolic needs 177 . One such process is macroautophagy (hereafter referred to as autophagy), which is a process of 'self-eating' whereby intracellular substrates are sequestered in doublemembrane vesicles known as autophagosomes 178 (FIG. 6) .
These autophagosomes can fuse to lysosomes, forming autophagolysosomes, in which the cargo is degraded by lysosomal hydrolases and then recycled back into the cytoplasm to be used in various metabolic reactions 178 . In cancer, the role of autophagy is complex and contextdependent [179] [180] [181] ; however, growing evidence has shown that in certain tumour types, such as those driven by oncogenic RAS, autophagy is required for tumour maintenance, largely to fuel the metabolism of these aggressive cancers [182] [183] [184] [185] . Indeed, inhibition of autophagy in this context either genetically or pharmacologically causes metabolic dysfunction and a decrease in tumour growth. There have been suggestions that the tumour suppressor gene background may dictate the role of autophagy in a given tumour type that has activating KRAS mutations. However, there are conflicting data in this regard, which could be due to differences in the various models used as well as to other factors [186] [187] [188] . Chloroquine and its derivative hydroxychloroquine (HCQ) can function as autophagy inhibitors, given their ability to inhibit lysosomal acidification 189, 190 . As they are already approved for use in patients for other indications and have been used safely for several decades, these drugs have now made their way into multiple clinical trials in various cancer types. RAS-driven cancers such as pancreatic cancer, in which nearly 100% of tumours possess activating KRAS mutations 191 , are highly represented in these trials. Although HCQ has been shown to be effective in the preclinical setting, there are many questions regarding its use in patients, including its pharmacological properties (for example, a long period of time is required to reach therapeutic levels) as well as its low potency 189 . Furthermore, as these drugs work at the level of the lysosome to inhibit the degradation of autophagosomal contents, they will probably interfere with other cellular processes. However, this interference may have antitumour benefits in that other processes such as macropinocytosis (discussed below) converge at the level of the lysosome. Whether HCQ is potent enough to inhibit autophagy in human tumours remains to be seen, and more potent autophagy inhibitors are in development. Given the multiple kinases involved in the process, as well as key components that are analogous to the ubiquitin conjugation system, there are several potential opportunities for the development or drugs to inhibit this pathway 192 . In addition to autophagy, which can generate metabolic substrates through intracellular degradation, RAS-transformed cells have developed other adaptations to essentially engulf extracellular proteins. It has been known since the 1980s that cells expressing RAS oncogenes undergo a process known as macropinocytosis, whereby a membrane process envelops extracellular contents 193 . This is then internalized and ultimately fuses to the lysosome, where, in a process similar to autophagy, the contents of the macropinosome are degraded. In contrast to autophagy, in which much of the machinery has been identified, much less is known about the proteins that are crucial for macropinocytosis 194 . Regardless of this, recent work has shown that, in the context of KRASmutant cancer cells, macropinocytosis may have a key metabolic role. Indeed, KRAS-transformed cells, including pancreatic cancer cells, use macropinocytosis to take up extracellular albumin, which is then degraded into amino acids and used to fuel the tricarboxylic acid (TCA) cycle 195 (FIG. 6) . In addition to proteins, RAS-transformed cells take up extracellular lipids and use these as their major source of fatty acids 196 . Taken together, these data show that RAS-driven cancers use multiple mechanisms to scavenge various metabolites and that there may be therapeutic opportunities in this regard as normal cells are not likely to be as reliant on these metabolic adaptations. In particular, as autophagy and macropinocytosis converge at the level of the lysosome, targeting degradation using HCQ or related inhibitors may have clinical benefits, and such trials are underway. 
Macropinocytosis
An actin-driven mechanism of endocytosis in which large fluid droplets are trapped in a large organelle originating from plasma membrane extensions (ruffles) of the cell surface.
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GlcN-6P
GlcNAc-6P GlcNAc-P UDP-GlcNAc Targeting metabolic changes. Several recent studies have shown that one of the major mechanisms by which oncogenic KRAS promotes tumour growth is by rewiring key aspects of metabolism in tumours. Mutant KRAS has been shown to increase glucose uptake and, conversely, low glucose conditions can select for tumour cells with KRAS mutations 197 . Work in pancreatic cancer systems has shown that oncogenic KRAS systematically controls glucose metabolism by promoting a transcriptional programme that leads to alterations of key rate-limiting Figure 6 | RAS-driven alterations in metabolism. RAS-mutant cancer cells are characterized by increased macropinocytosis and uptake of albumen, which leads to lysosomal degradation and to the release of amino acids. RAS-mutant cancer cells also have altered autophagy, which leads to the degradation of organelles and proteins and to the production of amino acids and other components that support metabolism. Oncogenic KRAS directs glucose metabolism into biosynthetic pathways in pancreatic ductal adenocarcinoma by upregulating many key enzymes in glycolysis. Oncogenic KRAS induces flux into the non-oxidative pentose phosphate pathway to fuel increased nucleic acid biosynthesis and activates the hexosamine biosynthesis and glycosylation pathways. Pancreatic ductal adenocarcinoma cells also use a non-canonical pathway to process glutamine to maintain redox status and to support growth. Blue boxes indicate metabolic enzymes that are affected by RAS-dependent changes in gene expression or protein activation, with arrows indicating increased or decreased expression. Yellow boxes indicate metabolic enzymes that are not known to be affected by RAS. ENO1, enolase 1; GFPT1, glucosamine-fructose-6-phosphate aminotransferase 1; GlcN, glucosamine; GlcNAc, N-acetylglucosamine; GLUD1, glutamate dehydrogenase 1; GLUT1, glucose transporter 1; GLS1, glutaminase 1; GOT, aspartate transaminase; GSH, glutathione; GSSG, glutathione disulphide; HK, hexokinase; MDH1, malate dehydrogenase 1; ME1, malic enzyme 1; LDHA, lactate dehydrogenase A; PFK1, phosphofructokinase 1; PKM, pyruvate kinase; ROS, reactive oxygen species; RPE, ribulose-5-phosphate-3-epimerase; RPIA, ribulose-5-phosphate isomerase; TCA, tricarboxylic acid; UDP, uridine diphosphate.
enzymes of anabolic glucose metabolism 15 (FIG. 6) . The net result of these changes is increased flux of glycolytic intermediates through pathways such as the hexosamine biosynthesis pathway (HBP) and the non-oxidative arm of the pentose phosphate pathway (PPP). This leads to increased production of precursors used for glycosylation (generated through the HBP) and ribose used for DNA and RNA biosynthesis (generated through the non-oxidative PPP). Importantly, inhibition of either of these pathways using shRNAs to KRAS-regulated enzymes inhibits pancreatic cancer growth in vitro and in xenografts 15 . Although no inhibitors of these enzymes are currently available, studies of KRAS signalling pathways that mediate the transcriptional and metabolic changes in anabolic glucose metabolism have provided a potential therapeutic approach. Indeed, the RAF− MEK−ERK pathway was shown to be crucial for the metabolic shift caused by oncogenic KRAS 15 . Clinical grade inhibitors of MEK are being tested in a variety of cancers and it may be possible to attenuate anabolic glucose metabolism in KRAS-mutant cancers using these compounds. Other studies have supported the approach of inhibiting various aspects of glucose metabolism in KRAS-driven tumours, including inhibition of lactate dehydrogenase 198 and hexokinase 2 (REF. 199 ). In addition to glucose metabolism, oncogenic KRAS seems to regulate a shift in glutamine metabolism in pancreatic and other cancer types 176, 200, 201 . In pancreatic cancers, KRAS seems to coordinate transcriptional changes that result in a net increase in flux through a novel pathway, whereby glutamine-derived aspartate is converted to oxaloacetate by cytosolic aspartate aminotransferase 1 (GOT1), then to malate by malate dehydrogenase 1 (MDH1), and finally to pyruvate and NADPH by the cytosolic malic enzyme 1 (ME1) (FIG. 6) . The NADPH that is generated from this series of reactions is crucial for growth because of its role in maintaining reduced glutathione pools for redox balance 176 . Importantly, this pathway was shown to be required for pancreatic cancer redox balance and growth in vitro and in vivo, although it was shown to be dispensable in normal cells; this therefore implies that compounds that inhibit this pathway may have a viable therapeutic index. There are currently no clinical grade inhibitors of GOT1, GOT2, MDH1 or ME1 available. However, inhibitors of glutaminase (GLS), which is the enzyme that catalyses the conversion of glutamine to glutamate, are available and are making their way into early phase clinical trials 202 . GLS inhibitors alter the redox balance in pancreatic cancer cells and synergize with treatments that increase reactive oxygen species (ROS) to inhibit pancreatic cancer growth 176 . Thus, there is potential to combine GLS inhibitors with treatments such as radiotherapy and chemotherapies that increase ROS. An important question remains as to whether these KRAS-regulated glucose and glutamine pathways are specific to pancreatic cancers or whether they are a common feature of all RAS-driven tumours; studies investigating this are ongoing. In this regard, it has been reported that inhibition of the aspartate aminotransferase in a breast cancer cell line with a KRAS mutation has antitumour effects 203 . An interesting theme emerging from studies of the metabolic changes driven by oncogenic KRAS is that this oncogene also has a prominent role in maintaining redox balance. This may be through the control of metabolic pathways that lead to increased NADPH production as mentioned above 176, 200 or alternatively through other mechanisms such as the upregulation of NRF2 (also known as NFE2L2), which is a master regulator of the cell's redox-based defence against ROS 204 . Indeed, it was shown that oncogenic KRAS, when expressed at endogenous levels, leads to decreased ROS levels in multiple cell types through the induction of the NRF2 antioxidant programme 205 . However, there is also evidence suggesting that KRAS-driven tumorigenesis requires ROS 201 . Therefore, it is likely that keeping a controlled level of ROS is beneficial for tumour growth, whereas disrupting redox homeostasis in KRAS-driven tumours may be an effective therapeutic strategy.
In conclusion, mounting evidence shows that one of the mechanisms by which oncogenic RAS supports tumour growth is by altering the metabolism of cancers. In many cases, these pathways remain crucial to tumour growth and therefore may provide tractable therapeutic opportunities for future drug development initiatives. While we await the development of novel inhibitors to various metabolic enzymes, some, such as GLS inhibitors, are already available for use. In addition, understanding how available compounds perturb metabolic pathways may facilitate a more rapid translation of preclinical findings to the clinic. Examples of new uses for older drugs include HCQ to inhibit autophagy and macropinocytosis, phenformin and metformin to inhibit mitochondrial complex I and MEK inhibitors to globally inhibit anabolic glucose metabolism in pancreatic cancers.
Conclusions and future prospects
As the general and military strategist Sun Tzu wrote in The Art of War -an influential ancient Chinese book on military strategy -success in battle is better achieved when we "know the enemy". More than 3 decades of intense research focused on RAS have provided an ever-increasingly comprehensive description of the target -we have repeatedly thought that we knew our enemy, RAS. Nevertheless, we have repeatedly failed to realize that our understanding has been far from complete and this failure has contributed to missteps and misdirections in RAS-targeted drug development. Now we can at least recognize that issues that we once thought to be understood are still works in progress. In particular, our view of RAS effector signalling, once thought to be a simple, linear unidirectional protein kinase cascade, has evolved to recognize a complex and highly dynamic signalling network that can adapt and rewire in response to pharmacological inhibitors. Other issues that remain poorly understood, but that will have considerable effects on successful RAS-targeted drug development, also need resolution. One probable basis for the failure of RAS-targeted drug discovery efforts is the still-prevalent assumption that activated RAS comes in one simple 'flavour' . There is now at least a greater appreciation that the three RAS isoforms are not functionally equivalent and that each will require distinct therapeutic approaches, which has resulted in the intense focus on KRAS.
Along the lines of RAS isoform differences, there remain the issues of why KRAS is mutated far more frequently than the other RAS isoforms and why some types of cancer have mutations almost exclusively in KRAS but not in the other RAS isoforms. In one study, this issue was addressed using a mouse model in which carcinogen-induced lung tumour formation is associated with a high frequency of Kras mutations 206 . In a mouse in which the genomic Kras locus was genetically engineered to express the HRAS protein instead, lung tumours arose at an even higher incidence and had Hras mutations. This result argues that it is not the RAS protein itself, but rather the KRAS regulatory locus, that favours KRAS mutations in human lung tumours. In contrast to this suggestion, a recent provocative study found that KRAS contains a high frequency of rare codons relative to HRAS, resulting in reduced protein translation 207 . When the KRAS gene was modified with more commonly used codons, KRAS protein expression was substantially higher and had more potent transforming activity. This result suggests that, as mutant RAS expression in normal cells lacking other genetic alterations causes senescence, low KRAS protein expression favours the persistence of histologically normal cells that have mutant KRAS, which thereby facilitates subsequent genetic events that then drive cancer progression. Then, once progression is initiated, higher mutant KRAS expression is needed to drive cancer growth; this may explain the KRAS gene amplification often seen in cancers. A crucial validation of this hypothesis would be the observation of a reduced incidence of mutant Krasinduced tumour formation in a mouse harbouring an endogenous codon-optimized Kras locus.
As a result of the predominant frequency of KRAS mutations in human cancers, in particular in cancers in dire need of improved therapies, the focus is now strongly on KRAS. As earlier studies had found that the KRAS4B splice variant is preferentially expressed, efforts are most focused on the KRAS4B protein. However, whether KRAS4A should still be considered to be a key player in cancer remains a neglected issue 208 . KRAS was originally discovered to be an oncogene when Werner Kirsten identified a murine leukaemia virus that transduced the rat cellular Kras gene. That this gene encodes KRAS4A is perhaps a reminder that this splice variant should not be completely ignored. Indeed, new unpublished data indicate that KRAS4A is more widely expressed in human cancers than has been previously appreciated and could also contribute to the transformed phenotype (F. D. Tsai, M. S. Lopes, M. Zhou, J. J. Fiordalisi, J. Gierut, K. M Haigis, M. R. Philips and A.D.C., unpublished observations).
Another less-appreciated possibility is that different KRAS mutations have distinct oncogenic properties and hence may be differentially responsive to targeted therapies. This possibility is suggested by the finding that patients with colorectal cancer whose tumours harbour KRAS G13D mutations, in contrast to G12 mutations, showed a clinical benefit from cetuximab, an epithelial growth factor receptor (EGFR)-targeted therapy 209, 210 . Similarly, in cell culture and mouse model analyses, KRAS G13D but not KRAS G12V colorectal cancer cells were sensitive to cetuximab. In a study of NSCLC, it was found that tumours with either KRAS G12C or KRAS
G12V
mutations correlated with worse progression-free survival compared with tumours with wild-type or other KRAS mutations 211 . A possible functional basis for this correlation was suggested by the finding that NSCLC cell lines with KRAS G12D preferentially activated the RAF and PI3K effector pathways, whereas those with KRAS G12C or KRAS G12V preferentially activated the RAL effector pathway. These and other studies have stimulated an awareness that we may need to pursue mutationspecific RAS-targeted strategies, and this awareness is reflected in the fact that the National Cancer Institute (NCI)-directed RAS Project (see Further Information) has identified KRAS with the G12D, G12V, G12C or G13D mutations as the four mutant proteins to target. However, any additional genetic alterations that co-occur with one specific KRAS mutation will also diversify the therapies required for efficacy. Wild-type RAS activation by indirect mechanisms, whether by upstream receptor tyrosine kinase activity or by the loss of RASGAP function will also probably require very distinct therapeutic approaches. Hence, one therapy will not fit all forms of activated RAS, and there will not be one simple RAStargeted drug for all situations.
Perhaps one of the more perplexing issues that remains far from understood is the role of wild-type RAS in the setting of mutant RAS. This issue has two seemingly conflicting aspects. On the one hand, there is evidence that wild-type KRAS can function as a tumour suppressor and can antagonize mutant KRAS oncogenicity [212] [213] [214] [215] . Consistently, a considerable subset of KRAS-mutant tumour cell lines is homozygous for the mutant allele. But how might wild-type KRAS antagonize mutationally activated KRAS -is the GDP-bound form of KRAS not simply an inactive protein? There are clues that RAS proteins may dimerize 216 ; perhaps a wild-type-mutant KRAS dimer is inactive. However, this tumour suppressor function may not hold true for wild-type NRAS 217 . On the other hand, other studies have found that wild-type RAS isoforms support the mutated RAS isoform 75, 218, 219 . Indeed, there is strong experimental evidence to support the necessity of the wild-type isoform in the context of the mutated isoform. However, the mechanistic relationship between the mutant and the wild-type proteins, and what activated wild-type RAS does that cannot be fulfilled by the mutated RAS isoform, remain unclear.
There are also other challenges: even if an inhibitor can be developed that effectively blocks mutant RAS function and has a marked therapeutic response, compensatory mechanisms will probably be triggered to overcome the RAS addiction of cancer cells, and such newly RASindependent cancer cells will probably drive the return of cancer growth 149, 150 . This idea is supported by the fact that mutant-RAS-driven cancer growth involves effector signalling networks that can also be activated by RASindependent mechanisms. A clear understanding of the mechanistic basis for such resistance will be required to successfully overcome it, perhaps by prompting effective rational combinations of therapies, whether these be conventional and targeted drugs or targeted inhibitors and synthetic lethal interactors 165 . An emerging and exciting new direction may come from recent advances in our understanding of the immunological underpinnings of the activities of mutant RAS 220 . For example, mutant KRAS induces granulocyte/ macrophage colony-stimulating factor (GM-CSF) secretion in mouse pancreatic tumour cells, which stimulates the expansion of immunosuppressive myeloid-derived suppressor cells (MDSCs) and blocks T cell-driven antitumour immunity 221, 222 . This altered cytokine expression and/or the MDSCs themselves might be exploitable for immunotherapeutic attack. Similarly, one focus of the NCI RAS Project involves mapping the surface of mutant KRAS to identify sites of tumour-selective immune recognition.
Finally, silencing of RAS using RNAi is another possible future direction. Although still not ready for routine use, progress continues to be made in addressing key limitations of RNAi-based therapies, particularly facilitating efficient delivery to and entry into tumour cells and obtaining the effective and prolonged gene suppression that will be required to achieve a clinical response 223 . In summary, although the task of developing effective therapeutic strategies for RAS-dependent cancers remains daunting, with new knowledge and strategies there is cautious optimism that what has previously been considered an impossible mission may become 'Mission Possible' .
